Date: 2014-10-22
Type of information: Treatment of the first patient
phase: 1
Announcement: treatment of the first patient
Company: Atara Biotherapeutics (USA - CA)
Product: STM 434
Action
mechanism: fusion protein. STM 434 is a soluble receptor fused to part of an antibody that is designed to block the growth factor activin A.
Disease: ovarian cancer, other solid tumors
Therapeutic area: Cancer - Oncology
Country: USA
Trial
details: This Phase I study is testing the safety, pharmacokinetics and effectiveness of STM 434 alone, or in combination with liposomal doxorubicin, in patients with ovarian cancer or other advanced solid tumors. (NCT02262455)
Latest
news: * On October 22, 2014, Atara Biotherapeutics, a drug development company with a focus on innovative therapies for patients with debilitating diseases, announced dosing of the first patient in its Phase 1 clinical study of STM 434, an activin inhibitor, in patients with ovarian cancer and other solid tumors. The study is designed to assess the safety, tolerability and efficacy of STM 434 as a single therapy and in combination with liposomal doxorubicin.
